FORCE advocates for families facing hereditary breast and ovarian cancer in areas such as access to care, research funding, insurance, and privacy.
FORCE endorsed HR 6836, the Clinical Treatment Act, which would ensure that states cover routine care costs for Medicaid enrollees who participate in approved clinical trials.
FORCE joined nearly 100 patient advocacy orgs in expressing concern about allowing Medicare Advantage plans to use step therapy. Read letter...
We joined in a letter encouraging the House Ways and Means Committee to make the 7.5% medical expense deduction permanent.
We sent a letter to Senator Collins (R-ME) seeking her leadership on national oral parity legislation.
FORCE signed on to a coalition letter urging the Senate to maintain the allowed medical expense deduction at 7.5% of one's adjusted gross income.
On March 6, 2018, the Food and Drug Administration (FDA) announced approval of a new direct-to-consumer genetic test for three BRCA mutations most commonly found in people with Ashkenazi Jewish (Eastern European) ancestry, often referred to as founder mutations. With thousands of known BRCA mutations, 23andMe’s “Personal Genome Service Genetic Health Risk (GHR) Report for BRCA1/BRCA2 (Selected Variants)” provides consumers with an extremely limited snapshot of potential hereditary cancer risk.